This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit/hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts.

The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c)at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants.

The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.

Provided are a Bifidobacterium animalis subsp. lactis i797, a method for the separation and purification thereof, and a use thereof. The strain was deposited in the China General Microbiological Culture Collection Center on Aug. 20, 2019, wherein the deposit address is Building 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO. 18403. The Bifidobacterium animalis subsp. lactis i797 can adjust the balance of intestinal flora, improve stool characteristics, and has a better survival rate in simulated digestive juice; in addition, after being stored at 37 C., a relatively high temperature which is suitable for the growth of lactic acid bacteria, same can successfully control post-acidification.

A probiotic for inhibiting growth of Proteus mirabilis, including a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof. A fermentation broth and an application of the probiotic are further provided.

The present disclosure belongs to the technical field of pet food technology, and specifically to a probiotic cat food for improving digestive function of pet cat and preparation method thereof. The probiotic cat food, composed of an ingredient and a probiotic composition, the probiotic composition is composed of Bifidobacterium animalis subsp.lactis U9 and Lactobacillus plantarum CR12. The present disclosure, by specific formula and processing technology (three-stage low-temperature baking+probiotic cold-spraying), not only protects vitamins, amino acids, and certain bioactive substances in the cat foods from being destroyed, but also improves the taste of the foods, enhances the digestibility, and effectively ensures the activity of the probiotic composition.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit/hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.